We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex reported revenues of $2.65 billion in the last reported quarter, representing a year-over-year change of +6.1%. EPS of -$12.83 for the same period compares with $3.89 a year ago.

BOSTON, August 01, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2024, and raised its full year ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.28% higher to $481.24 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 0.26% to $486.11 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0 ...

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The RMR Group (Nasdaq: RMR) today announced the early renewal of the Vertex Pharmaceuticals Incorporated (“Vertex”) lease for 1.1 million square feet of office and laboratory ...

View Vertex Pharmaceuticals Incorporated (VRTX) current and estimated P/E ratio data provided by Seeking Alpha.

Dividend stocks offer long-term investors unique benefits.